Program

Opening Session

6:00 p.m.-7:30 p.m.

Welcome Remarks
David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN
Roy S. Herbst, Yale University, New Haven, CT

Keynote Address: microRNAs and lung cancer
Frank J. Slack, Yale University, New Haven, CT

Welcome Reception

7:30 p.m.-9:00 p.m.

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 1: Biology of Lung Cancer

Session Co-Chairpersons: Jonathan M. Kurie, University of Texas MD Anderson Cancer Center, Houston, TX, and Eric B. Haura, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
8:00 a.m.-10:00 a.m.

Network models in oncogene-addicted lung cancer
Eric B. Haura

Mechanisms of lung cancer metastasis
Jonathan M. Kurie

Lung cancer stem cells, acquired vulnerabilities, and molecular portraits: Translation to the clinic
John D. Minna, UT Southwestern Medical Center, Dallas, TX

Defining the mechanisms of tumorigenesis by mutant EGFR using mouse models
Katerina A. Politi, Yale University, New Haven, CT

Discussion

Break

10:00 a.m.-10:30 a.m.

Plenary Session 2: The Genomic Landscape of Lung Cancer

Session Co-Chairpersons: William Pao, Vanderbilt University, Nashville, TN, and Tetsuya Mitsudomi, Aichi Cancer Center Hospital, Nagoya, Japan
10:30 a.m.-12:30 p.m.

Gene fusions in lung cancer
David G. Beer, University of Michigan, Ann Arbor, MI

Somatic genome alterations in human lung cancers
Matthew L. Meyerson, Dana-Farber Cancer Institute, Boston, MA

Genetic and genomic difference in lung cancer based on ethnicity
Tetsuya Mitsudomi

Title to be announced
William Pao

Discussion

Poster Session A / Lunch

12:30 p.m.–2:30 p.m.

Concurrent Sessions 1-2

2:30 p.m.-4:30 p.m.

• Concurrent Session 1: Combined Modality Treatment

  Session Co-Chairpersons: David R. Gius, Vanderbilt School of Medicine, Nashville, TN, and David Jablons, University of California, San Francisco, CA

  Stereotactic ablative radiotherapy (SABR) for lung cancer
  Jeffrey D. Bradley, Washington University Medical School, St. Louis, MO

  A genetic connection between aging, sirtuins and carcinogenesis
  David R. Gius

  Molecular detection of early nodules/VATS sublobar resection for small nodules
  David Jablons

  A prospective trial of SBRT boost for stage III non-small cell lung cancer
  Ronald C. McGarry, University of Kentucky, Lexington, KY

  Discussion

• Concurrent Session 2: Immunology and Lung Cancer

  Session Co-Chairpersons: David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Dmitry Gabrilovich, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  Regulation of T-cell function in cancer by activation of Notch signaling
  David P. Carbone

  Molecular mechanisms regulating synergistic effect of immunotherapy and chemotherapy of cancer
  Dmitry Gabrilovich

  Causes and consequences of acid pH in tumors
  Robert Gillies, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

  TSLP driven inflammation fosters development of epithelial tumors
  A. Karolina Palucka, Baylor Institute for Immunology Research, Dallas, TX

  Discussion

Concurrent Sessions 3-4

4:45 p.m.-6:15 p.m.

• Concurrent Session 3: Advocacy Session
  Transformational Research: Patient-Bench-Patient

  Session Co-Chairpersons: Bonnie J. Addario, Bonnie J. Addario Lung Cancer Foundation, San Carlos, CA, and Kim Norris, Lung Cancer Foundation of America, Los Angeles, CA

  Speakers:
  Bonnie J. Addario
  Michael Weitz, St. John's Health Center, Woodland Hills, CA
  Shane Dormady, Valley Medical Oncology Consultants, Mountain View, CA
  Steven Young, Addario Lung Cancer Medical Institute, San Carlos, CA
  David P. Carbone, Vanderbilt-Ingram Cancer Center, Nashville, TN
  Kim Norris

• Concurrent Session 4: Short Talks from Proffered Abstracts

  
  Integrating expression data improves mutational significance analysis of lung squamous carcinoma
  Bryan Hernandez, Broad Institute, Cambridge, MA
  
  The genetic status of the EGFR, K-ras, and EML4-ALK genes in multiple primary noninvasive lung adenocarcinomas
  Kenji Sugio, National Kyushu Cancer Center, Fukuoka, Japan
  
  NSCLC and SCLC mouse models mediated by lentiviral gene delivery
  Yifeng Xia, Salk Institute for Biological Studies, La Jolla, CA
  
  The tumor suppressor role of Wnt/B-Catenin pathway in development of small cell lung cancer
  Kwon-Sik Park, Stanford University, Palo Alto, CA
  
  A phase II study of sorafenib in patients with stage IV non-small cell lung cancer (NSCLC) with a K-ras mutation
  Wouter W. Mellema, VU University Medical Center, Amsterdam, The Netherlands
  
  Phase 1b/2 trial of HER3 inhibitor U3-1287 in combination with erlotinib in advanced NSCLC patients (pts): HERALD study
  Joachim von Pawel, Asklepios Fachkliniken Munich-Gauting, Gauting, Bavaria, Germany

Dinner on own / Evening off

6:15 p.m.-

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 3: Lung Cancer Screening: Imaging and Molecular Approaches

Session Co-Chairpersons: Denise Aberle, UCLA David Geffen School of Medicine, Los Angeles, CA, Christine Berg, National Cancer Institute, Rockville, MD, and Gabriella Sozzi, Fundacion IRCCS Instituto Nazionale dei Tumori, Milan, Italy
8:00 a.m.-10:00 a.m.

Implications for lung cancer of the NLST results
Christine Berg

Cost effectiveness of CT screening
Peter Bach, Memorial Sloan-Kettering Cancer Center, New York, NY

Role of biomarkers in the early detection of lung cancer
Pierre P. Massion, Vanderbilt University Medical Center, Nashville, TN

The inflammation-EMT-cancer initiating cell axis in the pathogenesis of lung cancer
Steven M. Dubinett, David Gerren School of Medicine at UCLA, Los Angeles, CA

Discussion

Break

10:00 a.m.-10:30 a.m.

Plenary Session 4: Molecular vs. Histological Classifications of Lung Cancer

Session Co-Chairpersons: Fred R. Hirsch, University of Colorado Denver, Aurora, CO, and Paul A. Bunn, Jr., University of Colorado Denver, Aurora, CO
10:30 a.m.–12:30 p.m.

The molecular pathology of adenocarcinoma versus histopathological classification
Elisabeth M.P. Brambilla, Hôpital A. Michallon, Grenoble, France

Pathology of lung neuroendocrine tumors: In search of evidence for classification
Ilona Linnoila, National Cancer Institute, Bethesda, MD

Molecular pathology of squamous cell carcinoma of the lung
Ignacio I. Wistuba, University of Texas MD Anderson Cancer Center, Houston, TX

Molecular and histological classifications of lung cancer inform each other
Marc Ladanyi, Memorial Sloan-Kettering Cancer Center, New York, NY

Discussion

Lunch on own / Free time

12:30 p.m.-2:30 p.m.

Concurrent Sessions 5-6

2:30 p.m.-4:30 p.m.

• Concurrent Session 5: Lung Cancer Prevention

  Session Co-Chairpersons: Waun Ki Hong, University of Texas MD Anderson Cancer Center, Houston, TX, and Avrum E. Spira, Boston University School of Medicine, Boston, MA

  Targeted lung cancer chemoprevention through reverse migration
  Waun Ki Hong

  New opportunities to manage early lung cancer
  James Mulshine, Rush University, Chicago, IL

  Molecular field cancerization
  Avrum E. Spira

  Risk prediction models for lung cancer
  Margaret Spitz, Baylor College of Medicine, Houston, TX

  Discussion

• Concurrent Session 6: Biological Implications for Circulating Tumor Cells and Biomarkers in Lung Cancer Progression

  Session Co-Chairpersons: Pierre P. Massion, Vanderbilt-Ingram Cancer Center, Nashville, TN, and Katerina A. Politi, Yale University, New Haven, CT

  A systems approach to the discovery of lung cancer biomarkers in circulation
  Samir Hanash, Fred Hutchinson Cancer Research Center, Seattle, WA

  miRNA and lung cancer: Early detection in high-risk subjects
  Gabriella Sozzi, Fundacion IRCCS Instituto Nazionale dei Tumori, Milan, Italy

  Elucidating cancer biomarkers using aptamers
  Weihong Tan, University of Florida, Gainesville, FL

  Multiplexer mutational profiling of CTCs in NSCLC
  John V. Heymach, University of Texas MD Anderson Cancer Center, Houston, TX

  Discussion

Poster Session B / Reception

4:30 p.m.–6:30 p.m.

Dinner on own / Evening off

6:30 p.m.-

Continental Breakfast

7:00 a.m.-8:00 a.m.

Plenary Session 5: New Molecular Targets/Novel Therapy

Session Co-Chairpersons: Garth Powis, University of Texas MD Anderson Cancer Center, Houston, TX, and Roy S. Herbst, Yale University, New Haven CT
8:00 a.m.–10:00 a.m.

Title to be announced
Jeffrey Engelman, Massachusetts General Hospital, Boston, MA

Dual inhibitors of FT and GGT-1 as novel therapeutic agents
Said Sebti, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL

Regulation of redox pathways in lung cancer therapy
Kenneth Tew, Medical University of South Carolina, Charleston, SC

Mechanisms and inhibition of mutant KRAS in non-small cell lung cancer
Garth Powis

Discussion

Break

10:00 a.m.-10:15 a.m.

Plenary Session 6: Bringing Personalized Therapy into the Clinic

Session Co-Chairpersons: Paul A. Bunn, Jr., University of Colorado Denver, Aurora, CO and Joan H. Schiller, UT Southwestern Medical Center, Dallas, TX
10:15 a.m.–12:15 p.m.

Lessons learned from the BATTLE trials: a step towards personalized medicine
Roy S. Herbst, Yale University, New Haven, CT

Bringing personalized therapy into the clinic: Can pathology deliver?
Keith Kerr, Aberdeen University Medical School, Aberdeen, Scotland

Integration of genomic testing into the management of NSCLC
Bruce Johnson, Dana-Farber Cancer Institute, Boston, MA

Cetuximab in NSCLC and predictive markers
Fred Hirsch, University of Colorado Cancer Center, Aurora, CO

Discussion

Departure